Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTENAFINE HYDROCHLORIDE vs ABELCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.
Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
Invasive fungal infections refractory to amphotericin B deoxycholate or in patients intolerant to that formulation,Aspergillosis,Candidiasis,Cryptococcosis,Blastomycosis,Histoplasmosis,Coccidioidomycosis,Zygomycosis,Fungal sinusitis,Empiric therapy in febrile neutropenic patients (off-label),Visceral leishmaniasis (off-label)
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life is approximately 120–180 hours (mean ~153 h) in adults with normal renal and hepatic function. This long half-life reflects slow redistribution from tissues and supports once-daily dosing after a loading regimen.
Not significantly metabolized; undergoes minimal hepatic metabolism via CYP enzymes (unknown specific isoforms).
Amphotericin B is not significantly metabolized in humans; it is eliminated primarily via biliary excretion with negligible renal metabolism.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Renal excretion is minimal (<1% unchanged drug); the primary route of elimination is via the hepatobiliary system, with the majority of the dose recovered in feces as unchanged drug and metabolites. Biliary/fecal elimination accounts for >90% of clearance.
Approximately 60–70% bound to plasma proteins, predominantly albumin.
More than 99% bound to plasma proteins, primarily to albumin and lipoproteins (e.g., LDL and HDL).
Not well characterized due to minimal systemic absorption; estimated volume of distribution is very low, consistent with extensive tissue binding or limited distribution.
Volume of distribution is approximately 0.5–1.0 L/kg, indicating extensive tissue distribution (e.g., liver, spleen, lung, kidney) with limited penetration into cerebrospinal fluid and vitreous humor.
Topical: Systemic bioavailability is less than 5% following topical administration; oral bioavailability has not been established as drug is not used systemically.
Not applicable; only administered intravenously. Oral bioavailability is negligible (less than 5%) due to poor gastrointestinal absorption and degradation in the GI tract.
No dose adjustment required; negligible systemic absorption.
No dosage adjustment required, but renal function should be monitored; consider dose adjustment if Cr Cl < 30 m L/min or if significant nephrotoxicity occurs (e.g., doubling of serum creatinine).
No dose adjustment required; negligible systemic absorption.
No specific adjustment; use with caution in severe hepatic impairment.
≥12 years: same as adult; <12 years: safety and efficacy not established; use only if clearly needed.
Same dosing as adults (5 mg/kg/day IV); safety and efficacy established.
No specific adjustment; same as adult dosing; monitor for skin irritation.
No specific adjustment, but monitor renal function and electrolyte balance due to higher risk of toxicity.
None.
WARNING: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections in patients intolerant to conventional amphotericin B deoxycholate or whose infection is refractory to that formulation. Not interchangeable with other amphotericin B products. Verify correct product prior to administration. Administer by intravenous infusion only.
For external use only.,Avoid contact with eyes, nose, mouth, and other mucous membranes.,Discontinue if irritation or sensitization occurs.,Not recommended for treatment of onychomycosis or scalp infections.
Nephrotoxicity: monitor renal function closely; may cause azotemia, hypokalemia, hypomagnesemia,Hypersensitivity reactions: anaphylaxis, bronchospasm, flushing, hypotension,Infusion-related reactions: fever, chills, rigors, headache, nausea, vomiting,Cardiotoxicity: arrhythmias, cardiac arrest (especially during rapid infusion),Hepatotoxicity: elevated liver enzymes, bilirubin,Hematologic toxicity: anemia, thrombocytopenia, leukopenia,Electrolyte disturbances: hypokalemia, hypomagnesemia, hyponatremia,Pulmonary toxicity: dyspnea, respiratory failure (rare),Prior to infusion: premedicate with antipyretics, antihistamines, and corticosteroids to reduce infusion reactions
Hypersensitivity to butenafine hydrochloride or any components of the formulation.
Hypersensitivity to amphotericin B or any component of the formulation,Concurrent administration with other nephrotoxic drugs (e.g., cyclosporine, tacrolimus, aminoglycosides) unless benefit outweighs risk,Severe pre-existing renal impairment (relative contraindication; use only if no alternative)
No clinically significant food interactions reported. Butenafine is applied topically and systemic absorption is minimal, so dietary restrictions are not required.
No known food interactions. Maintain adequate hydration.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.
Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. However, systemic fungal infections pose significant maternal and fetal risk if untreated. Use only if clearly needed.
Unknown if excreted in human milk; M/P ratio not established. Use with caution in nursing mothers; consider benefits vs risks.
It is not known whether amphotericin B is excreted in human milk. Because many drugs are excreted in human milk and due to the potential for adverse effects in nursing infants, the decision to discontinue nursing or discontinue the drug should be made, taking into account the importance of the drug to the mother. M/P ratio unknown.
No dose adjustment required based on pharmacokinetic changes in pregnancy; topical application has minimal systemic absorption.
No specific dosing adjustments are recommended for pregnancy. However, given the potential for renal impairment and electrolyte disturbances, close monitoring is warranted. Dose adjustments are primarily based on renal function, which may be altered in pregnancy.
Butenafine hydrochloride is a benzylamine antifungal with fungicidal activity against dermatophytes (e.g., Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum) and yeasts (Malassezia spp.). It inhibits squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis. Applied once or twice daily for 1–4 weeks depending on indication. For tinea pedis (athlete's foot), treatment should extend 1 week beyond resolution to prevent recurrence. Avoid occlusion unless directed; may increase irritation. Contraindicated in hypersensitivity to any component. For severe or resistant cases, consider combination with keratolytics (e.g., salicylic acid) to enhance penetration.
Monitor renal function and electrolytes closely; premedicate with diphenhydramine and acetaminophen to reduce infusion-related reactions; do not mix with saline or other electrolytes; administer via in-line filter (5 micron) only; ensure adequate hydration to prevent nephrotoxicity.
Apply butenafine cream exactly as prescribed: clean and dry the affected area before application.,Use enough medication to cover the affected skin and a small margin of healthy surrounding skin.,Wash your hands after applying, unless treating the hands.,Do not cover the treated area with bandages or dressings unless instructed by your doctor.,Complete the full course of treatment even if symptoms improve, to prevent recurrence.,Notify your doctor if no improvement after 2–4 weeks or if irritation, redness, or blistering occurs.,Avoid contact with eyes, mouth, nose, or broken skin; if accidental contact occurs, rinse with water.,Do not use for conditions other than those prescribed; butenafine is for external use only.
This medication is given intravenously and may cause fever, chills, or rigors during infusion.,Report any breathing difficulty, chest pain, or severe reaction immediately.,You may receive pre-medications to reduce side effects.,Stay well hydrated unless instructed otherwise.,Blood tests will be required to monitor kidney function and electrolytes.
"Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is primarily metabolized by CYP3A4 and CYP2C19. Butenafine, an antifungal agent, is also metabolized by CYP3A4. Concurrent use may inhibit the metabolism of butenafine, leading to increased systemic exposure and potential toxicity, including hepatotoxicity or QT prolongation."
"Ranolazine, an antianginal agent, inhibits CYP3A4 and CYP2D6, reducing the metabolism of Butenafine, an antifungal agent typically metabolized by these enzymes. This results in significantly elevated Butenafine serum concentrations, increasing the risk of systemic adverse effects such as hepatotoxicity and QT prolongation. Co-administration may lead to enhanced antifungal efficacy but also potential toxicity."
"Butenafine, an allylamine antifungal, inhibits squalene epoxidase, a key enzyme in ergosterol biosynthesis, leading to fungal cell death. Bepridil, a calcium channel blocker with class I antiarrhythmic properties, prolongs the QT interval by blocking cardiac potassium channels, increasing the risk of torsades de pointes. When combined, butenafine may further inhibit hERG potassium channels in cardiac myocytes, potentiating QT prolongation and elevating the risk of life-threatening ventricular arrhythmias, particularly in patients with preexisting QT prolongation or electrolyte abnormalities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTENAFINE HYDROCHLORIDE vs ABELCET, answered by our medical review team.
BUTENAFINE HYDROCHLORIDE is a Antifungal that works by Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. ABELCET is a Polyene antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTENAFINE HYDROCHLORIDE and ABELCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTENAFINE HYDROCHLORIDE is: 1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.. The standard adult dose of ABELCET is: 5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTENAFINE HYDROCHLORIDE and ABELCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTENAFINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.. ABELCET is classified as Category C. Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. How. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.